Affinage

B3GNT2

N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 · UniProt Q9NY97

Length
397 aa
Mass
46.0 kDa
Annotated
2026-06-09
61 papers in source corpus 17 papers cited in narrative 17 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

B3GNT2 is the major poly-N-acetyllactosamine (poly-LacNAc) synthase in mammals, a Golgi-resident type II transmembrane β1,3-N-acetylglucosaminyltransferase that both initiates and elongates poly-LacNAc by transferring GlcNAc in β1,3 linkage onto Galβ1,4GlcNAc-terminating acceptors, with marked preference for type II (LacNAc) over type 1 or O-glycan core 1 acceptors (PMID:9892646, PMID:11511811). B3gnt2-knockout mice lose the bulk of N-glycan polylactosamine across tissues, establishing it as the principal enzyme generating these chains in vivo (PMID:20816167). Crystal structures in unliganded, donor (UDP-GlcNAc)-, acceptor-, and product-bound states show a GT-A fold using a DxD motif to coordinate Mg2+ for donor binding, an acceptor pocket that contacts only the terminal Galβ1,4-GlcNAcβ1,3- disaccharide (rationalizing its dual specificity for N- and O-glycans), and a direct-displacement inverting catalytic mechanism; a novel N-terminal helical domain stabilizes the catalytic domain (PMID:33158990, PMID:33229435). Enzyme function depends on N-glycosylation at Asn219 and on an intact stem region (PMID:15737642), and the enzyme acts with B3GNT8 as an activity-enhancing heterocomplex and with the β1,6-branching enzyme GCNT2 to build branched poly-LacNAc (PMID:15917431, PMID:24105809). Functionally, B3GNT2-dependent poly-LacNAc decorates immune co-receptors CD28 and CD19 to restrain lymphocyte activation (PMID:20816167), and its overexpression on tumor cells coats surface ligands and receptors to disrupt tumor–T cell and tumor–NK cell interactions, conferring resistance to T cell and NK cell cytotoxicity and promoting immune evasion (PMID:35338135, PMID:38619967). Beyond immunity, B3GNT2 glycosylates the Wnt co-receptor LRP6 to enhance its plasma-membrane trafficking and Wnt/β-catenin signaling (PMID:36980204) and contributes to endothelial secretion of Factor VIII and von Willebrand factor (PMID:38320121).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1999 High

    Established the core enzymatic identity, defining B3GNT2 as a β1,3-N-acetylglucosaminyltransferase that initiates and elongates poly-LacNAc with strict preference for type II LacNAc acceptors.

    Evidence cDNA cloning, recombinant expression, and in vitro enzyme assays with a defined acceptor specificity panel

    PMID:9892646

    Open questions at the time
    • In vivo physiological substrates not yet defined
    • Subcellular localization not directly demonstrated in this study
  2. 2000 High

    Confirmed the chemical linkage and Golgi residence, localizing the enzyme to the compartment where N-/O-glycan elongation occurs and verifying β1,3 GlcNAc addition to terminal Gal.

    Evidence Enzyme assay with proton NMR of product, subcellular fractionation, and Northern blot in the mouse ortholog

    PMID:11511811

    Open questions at the time
    • Did not address regulation of activity or partner enzymes
  3. 2005 High

    Showed the enzyme does not act alone — a B3GNT2–B3GNT8 heterocomplex markedly boosts catalytic efficiency, revealing a regulatory mode of assembly.

    Evidence In vitro kinetic assays of recombinant proteins and gel filtration to detect physical complex

    PMID:15917431

    Open questions at the time
    • Stoichiometry and in vivo prevalence of the heterocomplex not established
    • Structural basis of complex enhancement unknown
  4. 2005 High

    Defined post-translational and structural requirements for activity, showing N-glycosylation at Asn219 and an intact stem region are needed for catalysis and secretion.

    Evidence Site-directed mutagenesis of N-glycosylation sites, tunicamycin inhibition, and truncation analysis in baculovirus expression

    PMID:15737642

    Open questions at the time
    • Mechanism by which Asn219 glycan supports folding/activity not resolved
  5. 2010 High

    Demonstrated B3GNT2 is the dominant in vivo poly-LacNAc synthase and linked its product on CD28/CD19 to suppression of lymphocyte activation.

    Evidence B3gnt2-knockout mice with lectin blotting, glycan analysis, Ca2+ flux and proliferation assays on T and B cells

    PMID:20816167

    Open questions at the time
    • Direct molecular mechanism linking poly-LacNAc to receptor signaling thresholds not dissected
    • Other glycoprotein targets in immune cells not enumerated
  6. 2014 Medium

    Extended the target repertoire by identifying EGFR as a B3GNT2-associated glycoprotein and demonstrating cooperative poly-LacNAc synthesis with the branching enzyme GCNT2.

    Evidence Co-immunoprecipitation with EGFR in hepatocarcinoma cells; co-transfection of B3GNT2 and GCNT2 in HEK293T with lectin readout on adenylyl cyclase 3

    PMID:24105809 PMID:25605193

    Open questions at the time
    • EGFR association rests on a single Co-IP without reciprocal validation or mutagenesis
    • Functional consequence of EGFR glycosylation not tested
  7. 2016 Medium

    Connected B3GNT2 sequence variation to disease biology, showing colorectal-cancer mutations alter localization, modification, activity, and cell migration.

    Evidence Targeted re-sequencing with biochemical characterization of wild-type versus mutant enzyme plus migration assays

    PMID:27004849

    Open questions at the time
    • Causal contribution of individual mutations to tumor progression in vivo not established
  8. 2020 High

    Provided atomic-resolution mechanism: multiple crystal structures defined the GT-A fold, DxD/Mg2+ donor coordination, a disaccharide-recognizing acceptor pocket explaining dual N-/O-glycan specificity, and an inverting direct-displacement catalysis.

    Evidence X-ray crystallography of unliganded, donor-, acceptor-, and product-bound states with kinetics and mutagenesis (two independent studies)

    PMID:33158990 PMID:33229435

    Open questions at the time
    • Structure of the B3GNT2–B3GNT8 heterocomplex not solved
    • Conformational dynamics during catalysis only inferred
  9. 2022 Medium

    Defined a conformational determinant of catalytic efficiency, showing a hydrophobic-core residue toggles the catalytic base between 'D-in' and acceptor-accessible 'D-out' states.

    Evidence Site-directed mutagenesis (T336I), molecular dynamics simulations, and enzymatic assays

    PMID:35780833

    Open questions at the time
    • Physiological relevance of the D-in/D-out equilibrium not demonstrated
    • Single-lab MD-based mechanism
  10. 2022 High

    Established a causal role in tumor immune evasion, showing B3GNT2 overexpression coats multiple surface ligands/receptors with poly-LacNAc to blunt T cell killing.

    Evidence Genome-scale CRISPR activation screen, overexpression validation, mouse xenografts, and T cell cytotoxicity/interaction assays

    PMID:35338135

    Open questions at the time
    • Identity and relative contribution of the >10 individual surface targets not fully resolved
  11. 2023 Medium

    Identified a signaling target, showing B3GNT2 extends poly-LacNAc on LRP6 to enhance its surface trafficking and Wnt/β-catenin signaling.

    Evidence Expression screen with reciprocal gain/loss-of-function, glycan analysis of LRP6, trafficking and Wnt reporter assays

    PMID:36980204

    Open questions at the time
    • Whether LRP6 glycosylation is direct in vivo and dose-dependent in tissues not established
  12. 2024 High

    Generalized the immune-evasion mechanism to NK cells and to a regulatory axis, placing B3GNT2 downstream of SPPL3 loss as the transferase whose poly-LacNAc blocks NK receptor binding.

    Evidence Genome-wide CRISPR screen in SPPL3-deficient cells, mass spectrometry of N-glycans, and NK cytotoxicity assays with N-glycan maturation inhibition

    PMID:38619967

    Open questions at the time
    • NK receptors physically occluded by poly-LacNAc not individually mapped
  13. 2024 Medium

    Broadened the functional scope to hemostasis and to glyco-engineering tool use, linking B3GNT2 to endothelial FVIII/VWF secretion and demonstrating tolerance of unnatural UDP-GlcNAc donors.

    Evidence siRNA knockdown in human endothelial cells with FVIII/VWF release readouts; in vitro assays with azide/alkyne/diazirine UDP-GlcNAc analogs and cell-surface labeling

    PMID:38320121 PMID:38394345

    Open questions at the time
    • Mechanism connecting B3GNT2 glycosylation to FVIII/VWF secretory pathway not defined
    • Specific glycoprotein substrates in endothelial cells unidentified
  14. 2025 Medium

    Implicated B3GNT2 in sensory neurobiology, identifying it as a candidate effector of nociceptor sensitization induced by NGF/PKC.

    Evidence Deep visual proteomics and functional knockdown in cultured nociceptive neurons with a mechanical sensitization assay

    PMID:41965357

    Open questions at the time
    • Glycoprotein substrates mediating sensitization not identified
    • In vivo pain relevance not established; single study

Open questions

Synthesis pass · forward-looking unresolved questions
  • How B3GNT2 substrate selection is governed at the level of specific glycoprotein targets across tissues, and how the B3GNT2–B3GNT8 heterocomplex is structurally organized and regulated, remain open.
  • No structure of the active heterocomplex
  • Determinants of target glycoprotein choice in vivo unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 4
Localization
GO:0005794 Golgi apparatus 1
Pathway
R-HSA-168256 Immune System 3 R-HSA-392499 Metabolism of proteins 3 R-HSA-162582 Signal Transduction 1
Partners
B3GNT8EGFRGCNT2LRP6
Complex memberships
B3GNT2–B3GNT8 heterocomplex

Evidence

Reading pass · 17 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1999 B3GNT2 (beta3GnT) is a poly-N-acetyllactosamine synthase that both initiates and elongates poly-N-acetyllactosamine chains, showing marked preference for Gal(β1-4)Glc(NAc)-based acceptors; no activity was detected on type 1 Gal(β1-3)GlcNAc or O-glycan core 1 acceptors. The protein is a type II transmembrane polypeptide structurally related to β1,3-galactosyltransferases, sharing conserved amino acid motifs despite inverted donor/acceptor specificities. In vitro enzyme assay with defined acceptor substrates; substrate specificity panel; cDNA cloning and recombinant expression Proceedings of the National Academy of Sciences of the United States of America High 9892646
2000 Mouse B3GNT2 ortholog is a type II membrane protein localized to the Golgi apparatus, with enzyme activity preferring Gal(β1-4)Glc(NAc) acceptors; proton NMR confirmed incorporation of GlcNAc in β1,3 linkage to terminal Gal. The human gene maps to chromosome 2p15. Enzyme assay; NMR analysis of product; subcellular fractionation/localization; Northern blot Glycoconjugate journal High 11511811
2005 B3GNT2 and B3GNT8 form a heterocomplex that enhances enzymatic activity: when the two soluble recombinant enzymes are mixed, the Vmax/Km value is 9.3-fold higher than B3GNT2 alone and 160-fold higher than B3GNT8 alone. Both enzymes share similar substrate specificity, preferring tetraantennary N-glycans and 2,6-branched triantennary glycans. Gel filtration confirmed formation of a heterocomplex of ~110-210 kDa. In vitro enzyme activity assay of recombinant proteins; gel filtration chromatography to detect complex formation Glycobiology High 15917431
2005 N-glycosylation of B3GNT2 is required for enzymatic activity and secretion: four of five potential N-glycosylation sites are occupied. N-glycosylation at Asn219 is necessary for beta3GnT activity; N-glycosylation at Asn127 and Asn219 is critical for efficient protein secretion. The N-terminal region (stem region) is also important for maintaining active protein structure, as truncation of amino acids 1-82 abolishes activity. Site-directed mutagenesis of N-glycosylation sites; tunicamycin inhibition; truncation analysis; baculovirus expression system Biochemical and biophysical research communications High 15737642
2010 B3GNT2 is the major poly-N-acetyllactosamine (polylactosamine) synthase in vivo. B3gnt2-knockout mice show markedly reduced polylactosamine on N-glycans across tissues. Polylactosamine is present on immune co-stimulatory molecules CD28 and CD19; B3gnt2-/- T cells show hyperactivation (increased Ca2+ flux and proliferation) upon anti-CD3ε/CD28 stimulation, and B3gnt2-/- B cells show hyperproliferation upon BCR stimulation, indicating polylactosamine synthesized by B3GNT2 normally suppresses lymphocyte activation. Knockout mouse model; flow cytometry; LEL lectin-blotting; glycan analysis by metabolic labeling; lectin microarray; Ca2+ flux assay; proliferation assay Methods in enzymology High 20816167
2014 B3GNT2 co-immunoprecipitates with EGFR in H7721 hepatocellular carcinoma cells, identifying EGFR as a B3GNT2-targeting protein. Polylactosamine on EGFR is increased by EGF treatment and decreased by ATRA, correlating with altered B3GNT2 expression. Co-immunoprecipitation; RT-PCR for enzyme expression; lectin staining Asian Pacific journal of cancer prevention Medium 25605193
2014 Co-expression of B3GNT2 and GCNT2 (β1,6-branching glycosyltransferase) in HEK293T cells produces high levels of poly-N-acetyllactosamine (PLN) on the cell surface and on adenylyl cyclase 3, demonstrating cooperative function: GCNT2 generates β1,6-branches that are subsequently extended by B3GNT2 to generate PLN chains. Co-transfection of HEK293T cells; flow cytometry for cell-surface PLN; immunoprecipitation of adenylyl cyclase 3 with lectin detection Journal of cellular physiology Medium 24105809
2016 Mutations in B3GNT2 identified in colorectal cancer cell lines markedly alter protein localization, post-translational modification, and/or encoded enzymatic activities, and affect migratory potential of colon carcinoma cells, indicating these are functionally deleterious mutations contributing to aberrant glycosylation in CRC. Targeted re-sequencing; biochemical characterization of wild-type vs. mutant glycosyltransferases (localization, PTM, enzymatic activity assays); migration assay Scientific reports Medium 27004849
2020 Crystal structures of human B3GNT2 were determined in unliganded, donor substrate (UDP-GlcNAc)-bound, acceptor substrate-bound, and product-bound states (1.85–2.35 Å resolution). Kinetic studies show transglycosylation follows a sequential mechanism. Critical residues for donor and acceptor recognition and catalysis were identified; mutations of invariant residues impair B3GNT2 activity in cell assays. B3GNT2 contains a novel N-terminal helical domain that stabilizes the catalytic domain and may distinguish among acceptor substrates. X-ray crystallography (5 structures); kinetic assays; site-directed mutagenesis with cell-based activity assays The Journal of biological chemistry High 33158990
2020 Crystal structures of human B3GNT2 in complex with UDP:Mg2+ and with UDP:Mg2+ plus the acceptor lacto-N-neotetraose reveal: (1) B3GNT2 uses the GT-A fold with a DxD motif coordinating Mg2+ for UDP-GlcNAc donor binding; (2) the acceptor binding site contacts only the terminal Galβ(1,4)-GlcNAcβ(1,3)- disaccharide, explaining specificity for both N- and O-glycan acceptors; (3) modeling supports a direct displacement inverting catalytic mechanism. X-ray crystallography (donor-bound and donor+acceptor-bound complexes); structural modeling The Journal of biological chemistry High 33229435
2022 CRISPR activation screen identified B3GNT2 overexpression as conferring resistance to T cell-mediated cytotoxicity in melanoma cells and mouse xenografts. Mechanistically, B3GNT2 (a poly-N-acetyllactosamine synthase) targets >10 ligands and receptors on the tumor cell surface, disrupting interactions between tumor cells and T cells and reducing T cell activation. Genome-scale CRISPR activation screen; overexpression validation in multiple cancer cell types; mouse xenograft models; T cell cytotoxicity assays; analysis of tumor-T cell interactions Nature communications High 35338135
2022 Mutagenesis of B3GNT2 hydrophobic core residue T336I increases catalytic efficiency by modulating the conformational occupancy of the catalytic base between 'D-in' and acceptor-accessible 'D-out' conformations, as demonstrated by experimental mutational analysis and molecular dynamics simulations. Site-directed mutagenesis; molecular dynamics simulations; enzymatic activity assay The Journal of biological chemistry Medium 35780833
2023 B3GNT2 promotes extension of polylactosamine chains at multiple N-glycans on the Wnt co-receptor LRP6, enhancing LRP6 trafficking to the plasma membrane and promoting Wnt/β-catenin signaling. Both gain-of-function (B3GNT2 overexpression) and loss-of-function evidence support this role. Cell culture-based expression screen; gain-of-function and loss-of-function experiments; glycan analysis of LRP6; cell surface trafficking assay; Wnt/β-catenin reporter assay Cells Medium 36980204
2024 In a secondary CRISPR screen in SPPL3-deficient cells, B3GNT2 was identified as the transferase mediating poly-LacNAc extension on complex N-glycans that underlies resistance to NK cell cytotoxicity. Mass spectrometry confirmed enrichment of N-glycans bearing poly-LacNAc upon SPPL3 loss; inhibiting N-glycan maturation restored NK receptor binding and sensitivity. Genome-wide CRISPR screen; mass spectrometry of N-glycans; NK cytotoxicity assay; N-glycan maturation inhibition Cell reports High 38619967
2024 Silencing of B3GNT2 in human liver endothelial cells (HLECs) decreased release of Factor VIII (FVIII), and silencing of B3GNT2 in human vein endothelial cells decreased release of von Willebrand factor (VWF), demonstrating a functional role for B3GNT2 in FVIII and VWF secretion. siRNA knockdown in human endothelial cells; FVIII and VWF release measurement Blood Medium 38320121
2024 B3GNT2 tolerates modified UDP-GlcNAc donors bearing azide, alkyne, or diazirine groups at the C2-acetamido position for transfer to glycan acceptors (albeit less efficiently than natural UDP-GlcNAc), and can exo-enzymatically install GlcNAz on cell-surface glycans, enabling subsequent extension with B4GalT1 to form LacNAz motifs. In vitro enzyme assay with unnatural nucleotide-sugar substrates; cell-surface glyco-engineering with flow cytometric detection ACS chemical biology Medium 38394345
2025 Functional knockdown of B3GNT2 in nociceptive sensory neurons (which upregulate B3GNT2 after NGF/PKC sensitization) identified B3GNT2 as a potential effector of nociceptor sensitization, linking its glycosyltransferase activity to mechanical pain sensitization. Deep visual proteomics; functional knockdown experiments in cultured nociceptive neurons; mechanical sensitization assay Nature communications Medium 41965357

Source papers

Stage 0 corpus · 61 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Molecular cloning and characterization of a novel UDP-GlcNAc:GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase (beta 3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans. The Journal of biological chemistry 132 11821425
2022 CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nature communications 98 35338135
2001 Molecular cloning and characterization of UDP-GlcNAc:lactosylceramide beta 1,3-N-acetylglucosaminyltransferase (beta 3Gn-T5), an essential enzyme for the expression of HNK-1 and Lewis X epitopes on glycolipids. The Journal of biological chemistry 95 11283017
2005 A novel beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T8), which synthesizes poly-N-acetyllactosamine, is dramatically upregulated in colon cancer. FEBS letters 76 15620693
1999 A beta-1,3-N-acetylglucosaminyltransferase with poly-N-acetyllactosamine synthase activity is structurally related to beta-1,3-galactosyltransferases. Proceedings of the National Academy of Sciences of the United States of America 75 9892646
2023 Roles of glycosylation at the cancer cell surface: opportunities for large scale glycoproteomics. Theranostics 72 37215580
2013 Transcriptome study of differential expression in schizophrenia. Human molecular genetics 69 23904455
2003 Different glycosyltransferases are differentially processed for secretion, dimerization, and autoglycosylation. Glycobiology 53 14514709
2016 Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer. Scientific reports 48 27004849
2013 PADI4 and HLA-DRB1 are genetic risks for radiographic progression in RA patients, independent of ACPA status: results from the IORRA cohort study. PloS one 45 23577190
2016 RNA-Sequencing for profiling goat milk transcriptome in colostrum and mature milk. BMC veterinary research 44 27884183
2005 Characterization of a novel galactose beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T8): the complex formation of beta3Gn-T2 and beta3Gn-T8 enhances enzymatic activity. Glycobiology 44 15917431
2018 Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. Annals of the rheumatic diseases 43 30552173
2010 Beta3GnT2 (B3GNT2), a major polylactosamine synthase: analysis of B3GNT2-deficient mice. Methods in enzymology 43 20816167
2020 Structures and mechanism of human glycosyltransferase β1,3-N-acetylglucosaminyltransferase 2 (B3GNT2), an important player in immune homeostasis. The Journal of biological chemistry 33 33158990
2020 Comparison of human poly-N-acetyl-lactosamine synthase structure with GT-A fold glycosyltransferases supports a modular assembly of catalytic subsites. The Journal of biological chemistry 29 33229435
2004 beta1,3-N-Acetylglucosaminyltransferase-7 (beta3Gn-T7) acts efficiently on keratan sulfate-related glycans. FEBS letters 29 14706853
2007 Construction of a cysteine protease deficient Bombyx mori multiple nucleopolyhedrovirus bacmid and its application to improve expression of a fusion protein. Journal of virological methods 28 17543396
2005 Improvement of the production of GFPuv-beta1,3-N-acetylglucosaminyltransferase 2 fusion protein using a molecular chaperone-assisted insect-cell-based expression system. Biotechnology and bioengineering 27 15609270
2014 Knockdown of β3GnT8 reverses 5-fluorouracil resistance in human colorectal cancer cells via inhibition the biosynthesis of polylactosamine-type N-glycans. International journal of oncology 23 25269761
2004 Comparative analysis of GFP(UV)-beta1,3-N-acetylglucosaminyltransferase 2 production in two insect-cell-based expression systems. Protein expression and purification 23 15039066
2024 A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels. Blood 20 38320121
2007 Enhanced production of secretory beta1,3-N-acetylglucosaminyltransferase 2 fusion protein into hemolymph of Bombyx mori larvae using recombinant BmNPV bacmid integrated signal sequence. Journal of biotechnology 20 17346841
2005 The effects of N-glycosylation sites and the N-terminal region on the biological function of beta1,3-N-acetylglucosaminyltransferase 2 and its secretion. Biochemical and biophysical research communications 18 15737642
2017 rs2841277 (PLD4) is associated with susceptibility and rs4672495 is associated with disease activity in rheumatoid arthritis. Oncotarget 17 28969061
2011 Down-regulation of β-1,3-N-acetylglucosaminyltransferase-8 by siRNA inhibits the growth of human gastric cancer. Molecular medicine reports 14 21468598
2024 Functional genomics identifies N-acetyllactosamine extension of complex N-glycans as a mechanism to evade lysis by natural killer cells. Cell reports 13 38619967
2022 Typing characteristics of metabolism-related genes in osteoporosis. Frontiers in pharmacology 11 36188607
2022 Beta3Gn-T7 Is a Keratan Sulfate β1,3 N-Acetylglucosaminyltransferase in the Adult Brain. Frontiers in neuroanatomy 10 35221933
2014 N-linked polylactosamine glycan synthesis is regulated by co-expression of β3GnT2 and GCNT2. Journal of cellular physiology 10 24105809
2023 Imidazolone as an Amide Bioisostere in the Development of β-1,3-N-Acetylglucosaminyltransferase 2 (B3GNT2) Inhibitors. Journal of medicinal chemistry 9 37988652
2020 Metabolic engineering challenges of extending N-glycan pathways in Chinese hamster ovary cells. Metabolic engineering 9 32663509
2007 Specific expression of GFPuv-beta1,3-N-acetylglucosaminyltransferase 2 fusion protein in fat body of Bombyx mori silkworm larvae using signal peptide. Biochemical and biophysical research communications 9 17544364
2024 Glyco-Engineering Cell Surfaces by Exo-Enzymatic Installation of GlcNAz and LacNAz Motifs. ACS chemical biology 8 38394345
2024 Identifying prioritization of therapeutic targets for ankylosing spondylitis: a multi-omics Mendelian randomization study. Journal of translational medicine 8 39707330
2023 N-Glycosylation of LRP6 by B3GnT2 Promotes Wnt/β-Catenin Signalling. Cells 8 36980204
2021 Genetic effects of B3GNT2 on ankylosing spondylitis susceptibility and clinical manifestations in Taiwanese. Journal of the Formosan Medical Association = Taiwan yi zhi 8 34645591
2021 Identifying and Validating Differentially Methylated Regions in Newly Diagnosed Patients with Graves' Disease. DNA and cell biology 7 33617351
2014 B3GNT2, a polylactosamine synthase, regulates glycosylation of EGFR in H7721 human hepatocellular carcinoma cells. Asian Pacific journal of cancer prevention : APJCP 7 25605193
2022 Modularity of the hydrophobic core and evolution of functional diversity in fold A glycosyltransferases. The Journal of biological chemistry 6 35780833
2000 Molecular cloning and expression analysis of a mouse UDP-GlcNAc:Gal(beta1-4)Glc(NAc)-R beta1,3-N-acetylglucosaminyltransferase homologous to Drosophila melanogaster Brainiac and the beta1,3-galactosyltransferase family. Glycoconjugate journal 5 11511811
2011 Expression of β1,3-N-acetylglucosaminyltransferases during differentiation of human acute myeloid leukemia cells. Molecular and cellular biochemistry 4 21720768
2025 Metabolic engineering strategies for enhanced microbial synthesis of lacto-N-neotetraose: a key acetylated human milk oligosaccharide. Biotechnology advances 3 41475587
2018 Integrated PTR-ToF-MS, GWAS and biological pathway analyses reveal the contribution of cow's genome to cheese volatilome. Scientific reports 3 30451907
2025 Chemoenzymatic Synthesis and Biological Recognition of a Sulfonate Isostere of 6‑Sulfo-sialyl Lewisx. JACS Au 2 40747081
2024 Genetic background of walking ability and its relationship with leg defects, mortality, and performance traits in turkeys (Meleagris gallopavo). Poultry science 2 38788487
2024 Genome-wide comparative analyses highlight selection signatures underlying saline adaptation in Chilika buffalo. Physiological genomics 2 38949516
2024 Functional genomics implicates natural killer cells in the pathogenesis of ankylosing spondylitis. HGG advances 2 39468794
2025 Multi-omic insights from a multi-ancestry genome-wide meta-analysis of ankylosing spondylitis reveal novel pathways of disease susceptibility. Research square 1 40709250
2024 Rare Case of de Novo 2p15 Microdeletion Syndrome with Deletion Covering XPO1 and USP34 Genes Diagnosed in a Child - A Case Report. The application of clinical genetics 1 39050773
2005 Application of a radial-flow bioreactor in the production of beta1,3-N-acetylglucosaminyltransferase-2 fused with GFPuv using stably transformed insect cell lines. Biotechnology and applied biochemistry 1 15636581
2026 Psoriasis risk allele function in activated Th1/17 cells with "memory" to antigen exposure. PloS one 0 41811861
2026 Deep visual proteomics uncovers nociceptor diversity and pain targets. Nature communications 0 41965357
2026 Integrated Multi-Omics Strategies for Identifying Novel Therapies in Psoriasis. Bioinformatics (Oxford, England) 0 42209436
2025 A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A. Genes and immunity 0 40263602
2025 Insights into Convergent Evolution From Studying Amino Acid Patterns in Independent Lineages of Birds. Genome biology and evolution 0 40452433
2025 B3GNT2, GPR35, PSMG1 Gene Polymorphisms Are Related With Susceptibility and Severity of Ankylosing Spondylitis in Chinese Han Population. Molecular genetics & genomic medicine 0 40736072
2025 Single-cell glycome and transcriptome profiling uncovers the glycan signature of each cell subpopulation of human iPSC-derived neurons. Stem cell reports 0 40912258
2025 Metabolic reprogramming and M2 macrophage depletion define the microenvironment of adenomyosis. Frontiers in endocrinology 0 41356013
2024 Functional genomics implicates natural killer cells in the pathogenesis of ankylosing spondylitis. medRxiv : the preprint server for health sciences 0 37808698
2023 A Scan of Pleiotropic Immune Mediated Disease Genes Identifies Novel Determinants of Baseline FVIII Inhibitor Status in Hemophilia-A. Research square 0 37886476

Missed literature

Know a paper Affinage missed for B3GNT2? Flag it for the maintainers and the community.

No submissions yet.